Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pacira BioSciences, Inc. - Common Stock
(NQ:
PCRX
)
20.75
+0.07 (+0.34%)
Streaming Delayed Price
Updated: 10:46 AM EST, Feb 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pacira BioSciences, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path
↗
August 12, 2024
Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,...
Via
Benzinga
Topics
Intellectual Property
Where Pacira BioSciences Stands With Analysts
↗
August 12, 2024
Via
Benzinga
JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
August 12, 2024
Via
Benzinga
Expert Ratings For Pacira BioSciences
↗
July 25, 2024
Via
Benzinga
NASDAQ:PCRX: good value for what you're paying.
↗
June 26, 2024
For those who appreciate value investing, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is a compelling option with its solid fundamentals.
Via
Chartmill
NASDAQ:PCRX, an undervalued stock with good fundamentals.
↗
June 05, 2024
Despite its impressive fundamentals, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) remains undervalued.
Via
Chartmill
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
August 09, 2024
From
Pacira BioSciences
Via
GlobeNewswire
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
↗
August 08, 2024
In a market where value is scarce, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024
↗
July 30, 2024
PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Pacira BioSciences Reports Second Quarter 2024 Financial Results
July 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
3 Biotech Stocks to Buy on the Dip: July 2024
↗
July 29, 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip.
Via
InvestorPlace
Analyst Ratings For Pacira BioSciences
↗
May 08, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
↗
April 09, 2024
Via
Benzinga
Pacira to Report Second Quarter 2024 Financial Results on Tuesday July 30, 2024
July 23, 2024
From
Pacira BioSciences
Via
GlobeNewswire
In a market where value is scarce, NASDAQ:PCRX offers a refreshing opportunity with its solid fundamentals.
↗
July 17, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
July 10, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Top 5 Health Care Stocks That May Explode In July
↗
July 08, 2024
Via
Benzinga
This Charter Communications Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday
↗
July 03, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
↗
July 02, 2024
Via
Benzinga
Pacira BioSciences to Participate in Fireside Chat at the 2024 Jefferies Global Healthcare Conference
May 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
When you look at NASDAQ:PCRX, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
↗
May 15, 2024
When you look at PACIRA BIOSCIENCES INC (NASDAQ:PCRX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
May 10, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
May 08, 2024
From
Pacira BioSciences
Via
GlobeNewswire
PCRX Stock Earnings: Pacira BioSciences Meets EPS, Beats Revenue for Q1 2024
↗
May 07, 2024
PCRX stock results show that Pacira BioSciences met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
May 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
May 07, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
April 30, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Pacira BioSciences
Via
GlobeNewswire
Despite its impressive fundamentals, NASDAQ:PCRX remains undervalued.
↗
March 28, 2024
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
